Emavusertib

Emavusertib
Identifiers
	IUPAC name N-[5-[(3R)-3-hydroxypyrrolidin-1-yl]-2-morpholin-4-yl-[1,3]oxazolo[4,5-b]pyridin-6-yl]-2-(2-methylpyridin-4-yl)-1,3-oxazole-4-carboxamide;
CAS Number	1801344-14-8 ;
PubChem CID	118224491 ;
DrugBank	DB18060 ;
ChemSpider	84492187 ;
UNII	MH5DMF9JKY ;
ChEMBL	ChEMBL4783351 ;
Chemical and physical data
Formula	C24H25N7O5
Molar mass	491.508 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES CC1=NC=CC(=C1)C2=NC(=CO2)C(=O)NC3=CC4=C(N=C3N5CC[C@H](C5)O)N=C(O4)N6CCOCC6;
	InChI InChI=1S/C24H25N7O5/c1-14-10-15(2-4-25-14)23-27-18(13-35-23)22(33)26-17-11-19-20(28-21(17)31-5-3-16(32)12-31)29-24(36-19)30-6-8-34-9-7-30/h2,4,10-11,13,16,32H,3,5-9,12H2,1H3,(H,26,33)/t16-/m1/s1; Key:SJHNWSAWWOAWJH-MRXNPFEDSA-N;

Last updated June 26, 2025

Emavusertib (CA-4948) is a drug which acts as a selective inhibitor of the enzyme Interleukin-1 receptor-associated kinase 4 (IRAK-4) and was developed for the treatment of some forms of cancer.^[1]^[2]^[3]

References

↑ Gummadi VR, Boruah A, Ainan BR, Vare BR, Manda S, Gondle HP, et al. (December 2020). "Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies". ACS Medicinal Chemistry Letters. 11 (12): 2374–2381. doi:10.1021/acsmedchemlett.0c00255. PMC 7734642 . PMID 33335659.
↑ Von Roemeling CA, Doonan BP, Klippel K, Schultz D, Hoang-Minh L, Trivedi V, et al. (May 2023). "Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases". Clinical Cancer Research. 29 (9): 1751–1762. doi:10.1158/1078-0432.CCR-22-1682. PMC 10150246 . PMID 36749885.
↑ Parrondo RD, Iqbal M, Von Roemeling R, Von Roemeling C, Tun HW (2023). "IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies". Frontiers in Immunology. 14: 1239082. doi: 10.3389/fimmu.2023.1239082 . PMC 10637517 . PMID 37954584.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Gummadi VR, Boruah A, Ainan BR, Vare BR, Manda S, Gondle HP, et al. (December 2020). "Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies". ACS Medicinal Chemistry Letters. 11 (12): 2374–2381. doi:10.1021/acsmedchemlett.0c00255. PMC 7734642 . PMID 33335659.

[2] Von Roemeling CA, Doonan BP, Klippel K, Schultz D, Hoang-Minh L, Trivedi V, et al. (May 2023). "Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases". Clinical Cancer Research. 29 (9): 1751–1762. doi:10.1158/1078-0432.CCR-22-1682. PMC 10150246 . PMID 36749885.

[3] Parrondo RD, Iqbal M, Von Roemeling R, Von Roemeling C, Tun HW (2023). "IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies". Frontiers in Immunology. 14: 1239082. doi: 10.3389/fimmu.2023.1239082 . PMC 10637517 . PMID 37954584.

[1]

[2]

[3]

Identifiers

IUPAC name N-[5-[(3R)-3-hydroxypyrrolidin-1-yl]-2-morpholin-4-yl-[1,3]oxazolo[4,5-b]pyridin-6-yl]-2-(2-methylpyridin-4-yl)-1,3-oxazole-4-carboxamide
CAS Number	1801344-14-8
PubChem CID	118224491
DrugBank	DB18060
ChemSpider	84492187
UNII	MH5DMF9JKY
ChEMBL	ChEMBL4783351
Chemical and physical data
Formula	C₂₄H₂₅N₇O₅
Molar mass	491.508 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1=NC=CC(=C1)C2=NC(=CO2)C(=O)NC3=CC4=C(N=C3N5CC[C@H](C5)O)N=C(O4)N6CCOCC6
InChI InChI=1S/C24H25N7O5/c1-14-10-15(2-4-25-14)23-27-18(13-35-23)22(33)26-17-11-19-20(28-21(17)31-5-3-16(32)12-31)29-24(36-19)30-6-8-34-9-7-30/h2,4,10-11,13,16,32H,3,5-9,12H2,1H3,(H,26,33)/t16-/m1/s1 Key:SJHNWSAWWOAWJH-MRXNPFEDSA-N

Emavusertib

See also

References